Oracle will integrate Nuance Communications' cloud-based medical speech recognition technology
Focused on improving productivity of clinical programs, reducing costs, and boosting study participant retention, health sciences organizations seek ways to accelerate and streamline clinical trial data collection and management. To support these objectives, Oracle will integrate Nuance Communications' (NASDAQ: NUAN) cloud-based medical speech recognition technology with Oracle Health Sciences e-clinical software.
News Facts
“Nuance’s medical speech and language understanding solutions allow people to stay productive by leveraging mobile devices, and cloud connectivity to communicate anywhere, anytime across devices and platforms,” said Peter Durlach, senior vice president marketing, Nuance Communications. “Embedding Nuance cloud-based medical speech solutions into Oracle’s clinical apps provides a more natural and efficient approach for clinical researchers and staff to deliver accurate information within their workflow.”
· “Clinical trial sponsors and contract research organizations around the world count on Oracle Health Sciences’ leading e-clinical solutions to help them automate and streamline their entire clinical development process,” said Nick Giannasi, vice president, Oracle Health Sciences. “We are committed to continued innovation, and working with Nuance will bring powerful voice-driven capabilities to our e-clinical solutions, making it easier and faster for investigators and study participants to capture and provide accurate clinical trial data.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.